Conditions: Hypertension
Keywords: Essential hypertension Uncontrolled hypertension Antihypertensive agents Blood pressure
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 278
Healthy volunteers: no

Brief summary:
This study is being conducted to evaluate the safety of MK-0954A (L100/H12.5 mg) in essential hypertension participants who are uncontrolled with MK-954H (L50/H12.5 mg).

Detailed description:

Arms:
arm 1: One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 50 mg (L50) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will then receive open label MK-0954A (L100/H12.5) orally, once daily for 44 weeks (extension) arm 2: One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 100 mg (L100) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will continue to receive MK-0954A orally, once daily for 44 week extension

Interventions: intervention 1: MK-0954A intervention 2: MK-954H intervention 3: Placebo to MK-0954A intervention 4: Placebo to MK-954H
Intervention descriptions: intervention 1: Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily intervention 2: Tablet containing losartan potassium (50 mg) and hydrochlorothiazide (12.5 mg), once daily intervention 3: Placebo tablet to match MK-0954A, once daily intervention 4: Placebo tablet to match MK-954H, once daily

Protocol document: